Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research BILLERICA, Mass. --(BUSINESS WIRE)--May 10, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision

BILLERICA, Mass. --(BUSINESS WIRE)--May 3, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2022 before the start of trading

Blood-based assay has the potential to serve the multiple sclerosis (MS) community in management of relapsing-remitting form of the disease BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 22, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing

Company’s ultra-sensitive biomarker technology supports milestone achievement in establishing a method for clinicians to identify and interpret elevated values of sNfL in individual patients BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 4, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company

Funding will power a series of prospective clinical trials to validate Quanterix’ multi-analyte test in collaboration with Amsterdam University Medical Centers (Amsterdam UMC) BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 29, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 9, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky will present in-person at the

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 3, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky will present virtually at The

Company strengthens balance sheet ending FY with GAAP total revenue growth increase of 28% led by strong performance in neuro-related studies and applications Executive leadership succession plan effective April 25, 2022 , to build on the Company's foundation for growth BILLERICA, Mass.

License agreement provides Quanterix access to Lilly’s P-tau217 antibody technology, creating pathways for plasma-based biomarkers for use in Alzheimer’s disease; Establishes framework for future collaboration and supports development of Quanterix tests to advance diagnosing and treating

Masoud Toloue , President of Quanterix and Diagnostics, to Become CEO and Join Board of Directors Kevin Hrusovsky , Chairman and CEO of Quanterix , to Assume Role as Executive Chairman of the Board Moves are Designed to Propel the Precision Health Vision and Catalyze the Next Chapter of Growth and